Welcome to our dedicated page for Sanuwave Health SEC filings (Ticker: SNWV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sanuwave Health, Inc. (SNWV) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K, proxy statements, and other regulatory documents. Sanuwave is a Nevada corporation whose common stock trades on NASDAQ under the symbol SNWV, and its filings offer detailed information on operations, governance, and financing.
Recent Forms 8-K describe results of operations and financial condition for specific quarters, including press releases announcing revenue, gross margin, operating income, and non-GAAP metrics such as EBITDA and Adjusted EBITDA. Other 8-K filings cover material definitive agreements, such as a secured credit facility with JPMorgan Chase Bank, N.A. that includes a term loan and revolving credit facility, and the termination of a prior debt facility with NH Expansion Credit Fund Holdings LP.
Additional 8-K items document corporate actions and governance events, including changes in executive officers, separation and release agreements, stockholder meeting results, and amendments to the 2024 Equity Incentive Plan. One filing also describes a license and option agreement related to intravascular shockwave patents and the subsequent exercise of the option by the licensee, resulting in a cash payment to Sanuwave.
Investors interested in capital structure and shareholder matters can review the company’s definitive proxy statement (DEF 14A), which discusses director elections, ratification of the independent registered public accounting firm, advisory votes on executive compensation, and details of the reverse stock split of Sanuwave’s common stock.
On Stock Titan, these filings are updated from the SEC’s EDGAR system, and AI-powered tools can help summarize key points, highlight significant items in Forms 8-K, and clarify the implications of proxy proposals and financing agreements. This allows readers to quickly understand how Sanuwave’s regulatory disclosures relate to its advanced wound care and regenerative medicine business.
SANUWAVE Health has filed a Form 144 notice indicating a proposed sale of 155,373 shares of common stock with an aggregate market value of $5,058,944.88. The securities were originally acquired on October 18, 2024, through the conversion of convertible notes and warrants into common stock.
Key transaction details:
- Broker: Vanguard Marketing Corporation (El Paso, TX)
- Trading Venue: NASDAQ
- Planned Sale Date: June 25, 2025
- Total Outstanding Shares: 8,555,616
The Form 144 indicates that the seller has no material adverse information about SANUWAVE's operations that hasn't been publicly disclosed. No other securities sales by the same person were reported in the past 3 months. This planned sale represents approximately 1.82% of the company's outstanding shares.